Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease

被引:85
作者
Popoli, Patrizia
Blum, David
Martire, Alberto
Ledent, Catherine
Ceruti, Stefania
Abbracchio, Maria P.
机构
[1] Ist Super Sanita, Dept Drug Res & Evaluat, I-00161 Rome, Italy
[2] INSERM, Jean Pierre Aubert Res Ctr, U815, IFR114, F-59045 Lille, France
[3] Univ Lille 2, Fac Med, Lille, France
[4] ULB, IRIBHN, Brussels, Belgium
[5] Univ Milan, Dept Pharmacol Sci, I-20122 Milan, Italy
关键词
adenosine A(2A) receptors; Huntington's disease; neuroprotection; neurodegenerative mechanisms;
D O I
10.1016/j.pneurobio.2006.12.005
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The aim of this review is to summarize and critically discuss the complex role played by adenosine A(2A) receptors (A(2A)Rs) in Huntington's disease (HD)). Since A(2A)Rs are mainly localized on the neurons, which degenerate early in HD, and given their ability to stimulate glutamate outflow and inflammatory gliosis, it was hypothesized that they could be involved in the pathogenesis of HD, and that A(2A)R antagonists could be neuroprotective. This was further sustained by the demonstration that A(2A)Rs and underlying signaling systems undergo profound changes in cellular and animal models of HD. More recently, however, the equation A(2A) receptor blockade = neuroprotection has appeared too simplistic. First, it is now definitely clear that, besides mediating 'bad' responses (for example, stimulation of glutamate outflow and excessive glial activation), A(2A)Rs also promote 'good' responses (such as trophic and antinflammatory effects). This implies that A(2A)R blockade results either in pro-toxic or neuroprotective effects according to the mechanisms involved in a given experimental model. Second, since HD is a chronically progressive disease, the multiple mechanisms involving A(2A)Rs may play different relative roles along the degenerative process. Such different mechanisms can be influenced by A(2A)R activation or blockade in different ways, even leading to opposite outcomes depending on the time of agonist/antagonist administration. The number, and the complexity, of the possible scenarios is further increased by the influence of mutant Huntingtin on both the expression and functions of A(2A)Rs, and by the strikingly different effects mediated by A(2A)Rs expressed by different cell populations within the brain. (C) 2007 Published by Elsevier Ltd.
引用
收藏
页码:331 / 348
页数:18
相关论文
共 181 条
  • [1] ADENOSINE MODULATES THE DOPAMINERGIC FUNCTION IN THE NIGRO-STRIATAL SYSTEM BY INTERACTING WITH STRIATAL DOPAMINE DEPENDENT ADENYLATE-CYCLASE
    ABBRACCHIO, MP
    COLOMBO, F
    DILUCA, M
    ZARATIN, P
    CATTABENI, F
    [J]. PHARMACOLOGICAL RESEARCH COMMUNICATIONS, 1987, 19 (04): : 275 - 286
  • [2] Abbracchio MP, 1995, MOL PHARMACOL, V48, P1038
  • [3] Abbracchio MP, 1998, DRUG DEVELOP RES, V45, P379, DOI 10.1002/(sici)1098-2299(199811/12)45:3/4<379::aid-ddr38>3.0.co
  • [4] 2-y
  • [5] Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's diseases
    Alexi, T
    Borlongan, CV
    Faull, RLM
    Williams, CE
    Clark, RG
    Gluckman, PD
    Hughes, PE
    [J]. PROGRESS IN NEUROBIOLOGY, 2000, 60 (05) : 409 - 470
  • [6] Alfinito PD, 2003, J NEUROSCI, V23, P10982
  • [7] Anterograde transport of brain-derived neurotrophic factor and its role in the brain
    Altar, CA
    Cai, N
    Bliven, T
    Juhasz, M
    Conner, JM
    Acheson, AL
    Lindsay, RM
    Wiegand, SJ
    [J]. NATURE, 1997, 389 (6653) : 856 - 860
  • [8] Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
    Arrasate, M
    Mitra, S
    Schweitzer, ES
    Segal, MR
    Finkbeiner, S
    [J]. NATURE, 2004, 431 (7010) : 805 - 810
  • [9] Minocycline in phenotypic models of Huntington's disease
    Bantubungi, K
    Jacquard, C
    Greco, A
    Pintor, A
    Chtarto, A
    Tai, K
    Galas, MC
    Tenenbaum, L
    Déglon, N
    Popoli, P
    Minghetti, L
    Brouillet, E
    Brotchi, J
    Levivier, M
    Scbiffmann, SN
    Blum, D
    [J]. NEUROBIOLOGY OF DISEASE, 2005, 18 (01) : 206 - 217
  • [10] Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists
    Baraldi, PG
    Cacciari, B
    Spalluto, G
    Bergonzoni, M
    Dionisotti, S
    Ongini, E
    Varani, K
    Borea, PA
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (12) : 2126 - 2133